APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Homozygous Familial Hypercholesterolemia Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Homozygous Familial Hypercholesterolemia Treatment Market Analysis and Forecast 2026-2032

Report ID 173999010222 December 2025191 pages

Choose your research edition.

Industry ResearchHomozygous Familial Hypercholesterolemia Treatment Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Homozygous Familial Hypercholesterolemia Treatment Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Homozygous Familial Hypercholesterolemia Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Homozygous Familial Hypercholesterolemia Treatment Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Homozygous Familial Hypercholesterolemia Treatment Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Homozygous Familial Hypercholesterolemia Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Homozygous Familial Hypercholesterolemia Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Homozygous Familial Hypercholesterolemia Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Homozygous Familial Hypercholesterolemia Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Homozygous Familial Hypercholesterolemia Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Homozygous Familial Hypercholesterolemia Treatment include The Medicines Company, RegenxBio Inc, Regeneron Pharmaceuticals Inc, LipimetiX Development Inc, Gemphire Therapeutics Inc, Daewoong Co Ltd and CymaBay Therapeutics Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Homozygous Familial Hypercholesterolemia Treatment, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Homozygous Familial Hypercholesterolemia Treatment, also provides the sales of main regions and countries. Of the upcoming market potential for Homozygous Familial Hypercholesterolemia Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Homozygous Familial Hypercholesterolemia Treatment sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Homozygous Familial Hypercholesterolemia Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Homozygous Familial Hypercholesterolemia Treatment sales, projected growth trends, production technology, application and end-user industry.

Homozygous Familial Hypercholesterolemia Treatment Segment by Company

The Medicines Company

RegenxBio Inc

Regeneron Pharmaceuticals Inc

LipimetiX Development Inc

Gemphire Therapeutics Inc

Daewoong Co Ltd

CymaBay Therapeutics Inc

Homozygous Familial Hypercholesterolemia Treatment Segment by Type

Alirocumab

Evinacumab

AEM-2814

AEM-2802

Others

Homozygous Familial Hypercholesterolemia Treatment Segment by Application

Clinic

Hospital

Others

Homozygous Familial Hypercholesterolemia Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Homozygous Familial Hypercholesterolemia Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Homozygous Familial Hypercholesterolemia Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Homozygous Familial Hypercholesterolemia Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Homozygous Familial Hypercholesterolemia Treatment in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Homozygous Familial Hypercholesterolemia Treatment manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Homozygous Familial Hypercholesterolemia Treatment sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Homozygous Familial Hypercholesterolemia Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Alirocumab Major Manufacturers Table 3. Evinacumab Major Manufacturers Table 4. AEM-2814 Major Manufacturers Table 5. AEM-2802 Major Manufacturers Table 6. Others Major Manufacturers Table 7. Global Homozygous Familial Hypercholesterolemia Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Clinic Major Manufacturers Table 9. Hospital Major Manufacturers Table 10. Others Major Manufacturers Table 11. Homozygous Familial Hypercholesterolemia Treatment Industry Trends Table 12. Homozygous Familial Hypercholesterolemia Treatment Industry Drivers Table 13. Homozygous Familial Hypercholesterolemia Treatment Industry Opportunities and Challenges Table 14. Homozygous Familial Hypercholesterolemia Treatment Industry Restraints Table 15. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2021-2026) & (US$ Million) Table 17. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2027-2032) & (US$ Million) Table 18. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Region (2021-2026) Table 19. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Region (2027-2032) Table 20. Global Homozygous Familial Hypercholesterolemia Treatment Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 21. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2021-2026) & (k units) Table 22. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2027-2032) & (k units) Table 23. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Region (2021-2026) Table 24. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Region (2027-2032) Table 25. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Manufacturers (2021-2026) Table 27. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Manufacturers (2021-2026) Table 29. Global Homozygous Familial Hypercholesterolemia Treatment Sales Price (US$/unit) of Manufacturers (2021-2026) Table 30. Global Homozygous Familial Hypercholesterolemia Treatment Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global Homozygous Familial Hypercholesterolemia Treatment Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global Homozygous Familial Hypercholesterolemia Treatment Manufacturers, Product Type & Application Table 33. Global Homozygous Familial Hypercholesterolemia Treatment Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global Homozygous Familial Hypercholesterolemia Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2021-2026) & (US$ Million) Table 38. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2027-2032) & (US$ Million) Table 39. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2021-2026) Table 40. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2027-2032) Table 41. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type 2021 VS 2025 VS 2032 (k units) Table 42. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2021-2026) & (k units) Table 43. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2027-2032) & (k units) Table 44. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2021-2026) Table 45. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2027-2032) Table 46. Global Homozygous Familial Hypercholesterolemia Treatment Price by Type (2021-2026) & (US$/unit) Table 47. Global Homozygous Familial Hypercholesterolemia Treatment Price by Type (2027-2032) & (US$/unit) Table 48. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2021-2026) & (US$ Million) Table 50. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2027-2032) & (US$ Million) Table 51. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application (2021-2026) Table 52. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application (2027-2032) Table 53. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application 2021 VS 2025 VS 2032 (k units) Table 54. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2021-2026) & (k units) Table 55. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2027-2032) & (k units) Table 56. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2021-2026) Table 57. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2027-2032) Table 58. Global Homozygous Familial Hypercholesterolemia Treatment Price by Application (2021-2026) & (US$/unit) Table 59. Global Homozygous Familial Hypercholesterolemia Treatment Price by Application (2027-2032) & (US$/unit) Table 60. The Medicines Company Company Information Table 61. The Medicines Company Business Overview Table 62. The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 63. The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 64. The Medicines Company Recent Development Table 65. RegenxBio Inc Company Information Table 66. RegenxBio Inc Business Overview Table 67. RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 69. RegenxBio Inc Recent Development Table 70. Regeneron Pharmaceuticals Inc Company Information Table 71. Regeneron Pharmaceuticals Inc Business Overview Table 72. Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 74. Regeneron Pharmaceuticals Inc Recent Development Table 75. LipimetiX Development Inc Company Information Table 76. LipimetiX Development Inc Business Overview Table 77. LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 79. LipimetiX Development Inc Recent Development Table 80. Gemphire Therapeutics Inc Company Information Table 81. Gemphire Therapeutics Inc Business Overview Table 82. Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 84. Gemphire Therapeutics Inc Recent Development Table 85. Daewoong Co Ltd Company Information Table 86. Daewoong Co Ltd Business Overview Table 87. Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 89. Daewoong Co Ltd Recent Development Table 90. CymaBay Therapeutics Inc Company Information Table 91. CymaBay Therapeutics Inc Business Overview Table 92. CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 94. CymaBay Therapeutics Inc Recent Development Table 95. North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2021-2026) & (US$ Million) Table 96. North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2027-2032) & (US$ Million) Table 97. North America Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2021-2026) & (k units) Table 98. North America Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2027-2032) & (k units) Table 99. North America Homozygous Familial Hypercholesterolemia Treatment Sales Price by Type (2021-2026) & (US$/unit) Table 100. North America Homozygous Familial Hypercholesterolemia Treatment Sales Price by Type (2027-2032) & (US$/unit) Table 101. North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2021-2026) & (US$ Million) Table 102. North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2027-2032) & (US$ Million) Table 103. North America Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2021-2026) & (k units) Table 104. North America Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2027-2032) & (k units) Table 105. North America Homozygous Familial Hypercholesterolemia Treatment Sales Price by Application (2021-2026) & (US$/unit) Table 106. North America Homozygous Familial Hypercholesterolemia Treatment Sales Price by Application (2027-2032) & (US$/unit) Table 107. North America Homozygous Familial Hypercholesterolemia Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. North America Homozygous Familial Hypercholesterolemia Treatment Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 109. North America Homozygous Familial Hypercholesterolemia Treatment Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 110. North America Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 111. North America Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2026) & (k units) Table 112. North America Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2027-2032) & (k units) Table 113. North America Homozygous Familial Hypercholesterolemia Treatment Sales Price by Country (2021-2026) & (US$/unit) Table 114. North America Homozygous Familial Hypercholesterolemia Treatment Sales Price by Country (2027-2032) & (US$/unit) Table 115. United States Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 116. Canada Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 117. Mexico Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 118. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2021-2026) & (US$ Million) Table 119. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2027-2032) & (US$ Million) Table 120. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2021-2026) & (k units) Table 121. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2027-2032) & (k units) Table 122. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Price by Type (2021-2026) & (US$/unit) Table 123. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Price by Type (2027-2032) & (US$/unit) Table 124. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2021-2026) & (US$ Million) Table 125. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2027-2032) & (US$ Million) Table 126. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2021-2026) & (k units) Table 127. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2027-2032) & (k units) Table 128. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Price by Application (2021-2026) & (US$/unit) Table 129. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Price by Application (2027-2032) & (US$/unit) Table 130. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 131. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 132. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 133. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 134. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2026) & (k units) Table 135. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2027-2032) & (k units) Table 136. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Price by Country (2021-2026) & (US$/unit) Table 137. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Price by Country (2027-2032) & (US$/unit) Table 138. Germany Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 139. France Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 140. U.K. Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 141. Italy Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 142. Russia Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 143. Spain Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 144. Netherlands Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 145. Switzerland Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 146. Sweden Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 147. Poland Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 148. China Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2021-2026) & (US$ Million) Table 149. China Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2027-2032) & (US$ Million) Table 150. China Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2021-2026) & (k units) Table 151. China Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2027-2032) & (k units) Table 152. China Homozygous Familial Hypercholesterolemia Treatment Sales Price by Type (2021-2026) & (US$/unit) Table 153. China Homozygous Familial Hypercholesterolemia Treatment Sales Price by Type (2027-2032) & (US$/unit) Table 154. China Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2021-2026) & (US$ Million) Table 155. China Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2027-2032) & (US$ Million) Table 156. China Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2021-2026) & (k units) Table 157. China Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2027-2032) & (k units) Table 158. China Homozygous Familial Hypercholesterolemia Treatment Sales Price by Application (2021-2026) & (US$/unit) Table 159. China Homozygous Familial Hypercholesterolemia Treatment Sales Price by Application (2027-2032) & (US$/unit) Table 160. Asia Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2021-2026) & (US$ Million) Table 161. Asia Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2027-2032) & (US$ Million) Table 162. Asia Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2021-2026) & (k units) Table 163. Asia Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2027-2032) & (k units) Table 164. Asia Homozygous Familial Hypercholesterolemia Treatment Sales Price by Type (2021-2026) & (US$/unit) Table 165. Asia Homozygous Familial Hypercholesterolemia Treatment Sales Price by Type (2027-2032) & (US$/unit) Table 166. Asia Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2021-2026) & (US$ Million) Table 167. Asia Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2027-2032) & (US$ Million) Table 168. Asia Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2021-2026) & (k units) Table 169. Asia Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2027-2032) & (k units) Table 170. Asia Homozygous Familial Hypercholesterolemia Treatment Sales Price by Application (2021-2026) & (US$/unit) Table 171. Asia Homozygous Familial Hypercholesterolemia Treatment Sales Price by Application (2027-2032) & (US$/unit) Table 172. Asia Homozygous Familial Hypercholesterolemia Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 173. Asia Homozygous Familial Hypercholesterolemia Treatment Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 174. Asia Homozygous Familial Hypercholesterolemia Treatment Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 175. Asia Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 176. Asia Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2026) & (k units) Table 177. Asia Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2027-2032) & (k units) Table 178. Asia Homozygous Familial Hypercholesterolemia Treatment Sales Price by Country (2021-2026) & (US$/unit) Table 179. Asia Homozygous Familial Hypercholesterolemia Treatment Sales Price by Country (2027-2032) & (US$/unit) Table 180. Japan Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 181. South Korea Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 182. India Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 183. Australia Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 184. Taiwan Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 185. Southeast Asia Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 186. SAMEA Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2021-2026) & (US$ Million) Table 187. SAMEA Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2027-2032) & (US$ Million) Table 188. SAMEA Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2021-2026) & (k units) Table 189. SAMEA Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2027-2032) & (k units) Table 190. SAMEA Homozygous Familial Hypercholesterolemia Treatment Sales Price by Type (2021-2026) & (US$/unit) Table 191. SAMEA Homozygous Familial Hypercholesterolemia Treatment Sales Price by Type (2027-2032) & (US$/unit) Table 192. SAMEA Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2021-2026) & (US$ Million) Table 193. SAMEA Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2027-2032) & (US$ Million) Table 194. SAMEA Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2021-2026) & (k units) Table 195. SAMEA Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2027-2032) & (k units) Table 196. SAMEA Homozygous Familial Hypercholesterolemia Treatment Sales Price by Application (2021-2026) & (US$/unit) Table 197. SAMEA Homozygous Familial Hypercholesterolemia Treatment Sales Price by Application (2027-2032) & (US$/unit) Table 198. SAMEA Homozygous Familial Hypercholesterolemia Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 199. SAMEA Homozygous Familial Hypercholesterolemia Treatment Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 200. SAMEA Homozygous Familial Hypercholesterolemia Treatment Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 201. SAMEA Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 202. SAMEA Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2026) & (k units) Table 203. SAMEA Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2027-2032) & (k units) Table 204. SAMEA Homozygous Familial Hypercholesterolemia Treatment Sales Price by Country (2021-2026) & (US$/unit) Table 205. SAMEA Homozygous Familial Hypercholesterolemia Treatment Sales Price by Country (2027-2032) & (US$/unit) Table 206. Brazil Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 207. Argentina Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 208. Chile Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 209. Colombia Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 210. Peru Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 211. Saudi Arabia Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 212. Israel Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 213. UAE Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 214. Turkey Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 215. Iran Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 216. Egypt Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Table 217. Key Raw Materials Table 218. Raw Materials Key Suppliers Table 219. Homozygous Familial Hypercholesterolemia Treatment Distributors List Table 220. Homozygous Familial Hypercholesterolemia Treatment Customers List Table 221. Research Programs/Design for This Report Table 222. Authors List of This Report Table 223. Secondary Sources Table 224. Primary Sources List of Figures Figure 1. Homozygous Familial Hypercholesterolemia Treatment Image Figure 2. Global Homozygous Familial Hypercholesterolemia Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Homozygous Familial Hypercholesterolemia Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Alirocumab Image Figure 5. Evinacumab Image Figure 6. AEM-2814 Image Figure 7. AEM-2802 Image Figure 8. Others Image Figure 9. Global Homozygous Familial Hypercholesterolemia Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Homozygous Familial Hypercholesterolemia Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 11. Clinic Image Figure 12. Hospital Image Figure 13. Others Image Figure 14. Global Homozygous Familial Hypercholesterolemia Treatment Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Figure 16. Global Homozygous Familial Hypercholesterolemia Treatment Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Region (2021-2032) Figure 19. Global Homozygous Familial Hypercholesterolemia Treatment Sales (2021-2032) & (k units) Figure 20. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 21. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico Homozygous Familial Hypercholesterolemia Treatment Sales YoY (2021-2032) & (k units) Figure 23. Europe Homozygous Familial Hypercholesterolemia Treatment Sales YoY (2021-2032) & (k units) Figure 24. China Homozygous Familial Hypercholesterolemia Treatment Sales YoY (2021-2032) & (k units) Figure 25. Asia (Excluding China) Homozygous Familial Hypercholesterolemia Treatment Sales YoY (2021-2032) & (k units) Figure 26. South America, Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales YoY (2021-2032) & (k units) Figure 27. Global Homozygous Familial Hypercholesterolemia Treatment Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global Homozygous Familial Hypercholesterolemia Treatment Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2021-2032) Figure 33. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 34. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2021-2032) Figure 36. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 37. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application (2021-2032) Figure 39. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 40. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2021-2032) Figure 42. North America Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Type (2021-2032) Figure 43. North America Homozygous Familial Hypercholesterolemia Treatment Sales Share by Type (2021-2032) Figure 44. North America Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Application (2021-2032) Figure 45. North America Homozygous Familial Hypercholesterolemia Treatment Sales Share by Application (2021-2032) Figure 46. North America Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Country (2021-2032) Figure 47. North America Homozygous Familial Hypercholesterolemia Treatment Sales Share by Country (2021-2032) Figure 48. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Type (2021-2032) Figure 49. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Share by Type (2021-2032) Figure 50. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Application (2021-2032) Figure 51. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Share by Application (2021-2032) Figure 52. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Country (2021-2032) Figure 53. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Share by Country (2021-2032) Figure 54. China Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Type (2021-2032) Figure 55. China Homozygous Familial Hypercholesterolemia Treatment Sales Share by Type (2021-2032) Figure 56. China Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Application (2021-2032) Figure 57. China Homozygous Familial Hypercholesterolemia Treatment Sales Share by Application (2021-2032) Figure 58. Asia Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Type (2021-2032) Figure 59. Asia Homozygous Familial Hypercholesterolemia Treatment Sales Share by Type (2021-2032) Figure 60. Asia Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Application (2021-2032) Figure 61. Asia Homozygous Familial Hypercholesterolemia Treatment Sales Share by Application (2021-2032) Figure 62. Asia Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Country (2021-2032) Figure 63. Asia Homozygous Familial Hypercholesterolemia Treatment Sales Share by Country (2021-2032) Figure 64. SAMEA Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Type (2021-2032) Figure 65. SAMEA Homozygous Familial Hypercholesterolemia Treatment Sales Share by Type (2021-2032) Figure 66. SAMEA Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Application (2021-2032) Figure 67. SAMEA Homozygous Familial Hypercholesterolemia Treatment Sales Share by Application (2021-2032) Figure 68. SAMEA Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Country (2021-2032) Figure 69. SAMEA Homozygous Familial Hypercholesterolemia Treatment Sales Share by Country (2021-2032) Figure 70. Homozygous Familial Hypercholesterolemia Treatment Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Homozygous Familial Hypercholesterolemia Treatment Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Alirocumab
  • Evinacumab
  • AEM-2814
  • AEM-2802
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • The Medicines Company
  • RegenxBio Inc
  • Regeneron Pharmaceuticals Inc
  • LipimetiX Development Inc
  • Gemphire Therapeutics Inc
  • Daewoong Co Ltd
  • CymaBay Therapeutics Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Homozygous Familial Hypercholesterolemia Treatment Market by Type
  3. 1.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Alirocumab
  5. 1.2.3 Evinacumab
  6. 1.2.4 AEM-2814
  7. 1.2.5 AEM-2802
  8. 1.2.6 Others
  9. 1.3 Homozygous Familial Hypercholesterolemia Treatment Market by Application
  10. 1.3.1 Global Homozygous Familial Hypercholesterolemia Treatment Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Clinic
  12. 1.3.3 Hospital
  13. 1.3.4 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Homozygous Familial Hypercholesterolemia Treatment Market Dynamics
  1. 2.1 Homozygous Familial Hypercholesterolemia Treatment Industry Trends
  2. 2.2 Homozygous Familial Hypercholesterolemia Treatment Industry Drivers
  3. 2.3 Homozygous Familial Hypercholesterolemia Treatment Industry Opportunities and Challenges
  4. 2.4 Homozygous Familial Hypercholesterolemia Treatment Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region
  3. 3.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2021-2026)
  5. 3.2.3 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2027-2032)
  6. 3.2.4 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Homozygous Familial Hypercholesterolemia Treatment Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region
  9. 3.4.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2021-2026)
  11. 3.4.3 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2027-2032)
  12. 3.4.4 Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Manufacturers
  2. 4.1.1 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Homozygous Familial Hypercholesterolemia Treatment Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Manufacturers
  6. 4.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Homozygous Familial Hypercholesterolemia Treatment Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Homozygous Familial Hypercholesterolemia Treatment Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Homozygous Familial Hypercholesterolemia Treatment Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Homozygous Familial Hypercholesterolemia Treatment Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Homozygous Familial Hypercholesterolemia Treatment Manufacturers, Product Type & Application
  13. 4.7 Global Homozygous Familial Hypercholesterolemia Treatment Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Homozygous Familial Hypercholesterolemia Treatment Market CR5 and HHI
  16. 4.8.2 2025 Homozygous Familial Hypercholesterolemia Treatment Tier 1, Tier 2, and Tier 3
5 Homozygous Familial Hypercholesterolemia Treatment Market by Type
  1. 5.1 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type
  2. 5.1.1 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type
  6. 5.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2021-2032)
  9. 5.3 Global Homozygous Familial Hypercholesterolemia Treatment Price by Type
6 Homozygous Familial Hypercholesterolemia Treatment Market by Application
  1. 6.1 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Application
  2. 6.1.1 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application
  6. 6.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2021-2032)
  9. 6.3 Global Homozygous Familial Hypercholesterolemia Treatment Price by Application
7 Company Profiles
  1. 7.1 The Medicines Company
  2. 7.1.1 The Medicines Company Company Information
  3. 7.1.2 The Medicines Company Business Overview
  4. 7.1.3 The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  6. 7.1.5 The Medicines Company Recent Developments
  7. 7.2 RegenxBio Inc
  8. 7.2.1 RegenxBio Inc Company Information
  9. 7.2.2 RegenxBio Inc Business Overview
  10. 7.2.3 RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  12. 7.2.5 RegenxBio Inc Recent Developments
  13. 7.3 Regeneron Pharmaceuticals Inc
  14. 7.3.1 Regeneron Pharmaceuticals Inc Company Information
  15. 7.3.2 Regeneron Pharmaceuticals Inc Business Overview
  16. 7.3.3 Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  18. 7.3.5 Regeneron Pharmaceuticals Inc Recent Developments
  19. 7.4 LipimetiX Development Inc
  20. 7.4.1 LipimetiX Development Inc Company Information
  21. 7.4.2 LipimetiX Development Inc Business Overview
  22. 7.4.3 LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  24. 7.4.5 LipimetiX Development Inc Recent Developments
  25. 7.5 Gemphire Therapeutics Inc
  26. 7.5.1 Gemphire Therapeutics Inc Company Information
  27. 7.5.2 Gemphire Therapeutics Inc Business Overview
  28. 7.5.3 Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  30. 7.5.5 Gemphire Therapeutics Inc Recent Developments
  31. 7.6 Daewoong Co Ltd
  32. 7.6.1 Daewoong Co Ltd Company Information
  33. 7.6.2 Daewoong Co Ltd Business Overview
  34. 7.6.3 Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  36. 7.6.5 Daewoong Co Ltd Recent Developments
  37. 7.7 CymaBay Therapeutics Inc
  38. 7.7.1 CymaBay Therapeutics Inc Company Information
  39. 7.7.2 CymaBay Therapeutics Inc Business Overview
  40. 7.7.3 CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  42. 7.7.5 CymaBay Therapeutics Inc Recent Developments
8 North America
  1. 8.1 North America Homozygous Familial Hypercholesterolemia Treatment Market Size by Type
  2. 8.1.1 North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2021-2032)
  3. 8.1.2 North America Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2021-2032)
  4. 8.1.3 North America Homozygous Familial Hypercholesterolemia Treatment Price by Type (2021-2032)
  5. 8.2 North America Homozygous Familial Hypercholesterolemia Treatment Market Size by Application
  6. 8.2.1 North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2021-2032)
  7. 8.2.2 North America Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2021-2032)
  8. 8.2.3 North America Homozygous Familial Hypercholesterolemia Treatment Price by Application (2021-2032)
  9. 8.3 North America Homozygous Familial Hypercholesterolemia Treatment Market Size by Country
  10. 8.3.1 North America Homozygous Familial Hypercholesterolemia Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Homozygous Familial Hypercholesterolemia Treatment Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Homozygous Familial Hypercholesterolemia Treatment Market Size by Type
  2. 9.1.1 Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2021-2032)
  3. 9.1.2 Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2021-2032)
  4. 9.1.3 Europe Homozygous Familial Hypercholesterolemia Treatment Price by Type (2021-2032)
  5. 9.2 Europe Homozygous Familial Hypercholesterolemia Treatment Market Size by Application
  6. 9.2.1 Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2021-2032)
  7. 9.2.2 Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2021-2032)
  8. 9.2.3 Europe Homozygous Familial Hypercholesterolemia Treatment Price by Application (2021-2032)
  9. 9.3 Europe Homozygous Familial Hypercholesterolemia Treatment Market Size by Country
  10. 9.3.1 Europe Homozygous Familial Hypercholesterolemia Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Homozygous Familial Hypercholesterolemia Treatment Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Homozygous Familial Hypercholesterolemia Treatment Market Size by Type
  2. 10.1.1 China Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2021-2032)
  3. 10.1.2 China Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2021-2032)
  4. 10.1.3 China Homozygous Familial Hypercholesterolemia Treatment Price by Type (2021-2032)
  5. 10.2 China Homozygous Familial Hypercholesterolemia Treatment Market Size by Application
  6. 10.2.1 China Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2021-2032)
  7. 10.2.2 China Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2021-2032)
  8. 10.2.3 China Homozygous Familial Hypercholesterolemia Treatment Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Homozygous Familial Hypercholesterolemia Treatment Market Size by Type
  2. 11.1.1 Asia Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2021-2032)
  3. 11.1.2 Asia Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2021-2032)
  4. 11.1.3 Asia Homozygous Familial Hypercholesterolemia Treatment Price by Type (2021-2032)
  5. 11.2 Asia Homozygous Familial Hypercholesterolemia Treatment Market Size by Application
  6. 11.2.1 Asia Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2021-2032)
  7. 11.2.2 Asia Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2021-2032)
  8. 11.2.3 Asia Homozygous Familial Hypercholesterolemia Treatment Price by Application (2021-2032)
  9. 11.3 Asia Homozygous Familial Hypercholesterolemia Treatment Market Size by Country
  10. 11.3.1 Asia Homozygous Familial Hypercholesterolemia Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Homozygous Familial Hypercholesterolemia Treatment Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Homozygous Familial Hypercholesterolemia Treatment Market Size by Type
  2. 12.1.1 SAMEA Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Homozygous Familial Hypercholesterolemia Treatment Price by Type (2021-2032)
  5. 12.2 SAMEA Homozygous Familial Hypercholesterolemia Treatment Market Size by Application
  6. 12.2.1 SAMEA Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Homozygous Familial Hypercholesterolemia Treatment Price by Application (2021-2032)
  9. 12.3 SAMEA Homozygous Familial Hypercholesterolemia Treatment Market Size by Country
  10. 12.3.1 SAMEA Homozygous Familial Hypercholesterolemia Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Homozygous Familial Hypercholesterolemia Treatment Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Homozygous Familial Hypercholesterolemia Treatment Value Chain Analysis
  2. 13.1.1 Homozygous Familial Hypercholesterolemia Treatment Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Homozygous Familial Hypercholesterolemia Treatment Production Mode & Process
  6. 13.2 Homozygous Familial Hypercholesterolemia Treatment Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Homozygous Familial Hypercholesterolemia Treatment Distributors
  9. 13.2.3 Homozygous Familial Hypercholesterolemia Treatment Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst